Aspirin and ticlopidine after routine coronary stenting: The gold standard as of 1999

Journal of Thrombosis and Thrombolysis

Volumn 7, Issue 3, 1999, Pages 233-239

  McCullough, Peter A ^a   Marks, Keisha R ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; TICLOPIDINE;

AGRANULOCYTOSIS; ANGINA PECTORIS; APLASTIC ANEMIA; BLEEDING; BONE MARROW SUPPRESSION; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LEUKOPENIA; NEUTROPENIA; PANCYTOPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOSIS; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0033061950     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008922925054     Document Type: Review

References (29)

1. Popma JJ, Coller BS, Ohman EM, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1995;108:486S-501S.
2. Pepine CJ, Holmes DRJ. Coronary artery stents. American College of Cardiology. J Am Coll, Cardiol 1996;28:782-794.
3. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasoundguided stent implantation. Circulation 1996;93:215-222.
4. Schatz RA. The evolution of antithrombotic therapy in coronary stenting. Am Heart J 1997;134:S78-S80.
5. 4a. Pomma JJ, Weitz J, Bittle JA, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998; 114:7285-7415.
6. Schomig A, Neumann FJ, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: Comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997;29:28-34.
7. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
8. Cutlip DE, Kalon KL, Baim DS, et al. Predictors and clinical outcomes of stent thrombosis - a pooled analysis of 5000 patients from multicenter randomized trials (abstr). Circulation 1998;98:I 495.
9. Kong DF, Califf RM. Post-procedure heparin: Boon or burden? Am Heart J 1998;136:183-185.
10. Albiero R, Hall P, Itoh A, et al. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation 1997;95:1145-1156.
11. Stalnikowicz-Darvasi R. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis. J Clin Gastroenterol 1995;21:13-16.
12. Roche Laboratories. Ticlid (ticlopidine hydrochloride) [product information]. Nutley, NJ, 1998.
13. Schuhlen H, Hadamitzky M, Walter H, et al. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Sehatz stent placement: Analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. Circulation 1997;95:2015-2021.
14. Steinhubl SR, Lauer MS, Mukherjee DP, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol 1998;32:1366-1370.
15. Szto G, Linnemeier T, Lewis S, et al. Safety of 10 days of ticlopidine after coronary stenting - a randomized comparison with 30 days: Strategic Alternatives with Ticlopidine in Stenting Study (SALTS) (abstr). J Am Coll Cardiol. 1998; 31:352.
16. Schuhlen H, Kastrati A, Hausleiter J, et al. Two or four-week ticlopidine therapy after coronary stent placement? (abstr) Circulation 1998;98:I572.
17. Wysowksi DK, Bacsanyi J. Blood dyscrasias and hematologic reactions in ticlopidine users. JAMA 1996;276:952.
18. Barnett H, Eliasziw M, Meldrum H. Prevention of ischemic stroke. N Engl J Med 1995;333:460.
19. Janzon L. The STIMS trial: The ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study. Vasc Med 1996;1:141-143.
20. Bennett C, Weinberg P, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Intern Med 1998;128:541-544.
21. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-1339.
22. Lablanche JM, McFadden EP, Bonnet JL, et al. Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management. Eur Heart J 1996;17:1373-1380.
23. Goods CM, Al-Shaibi KF, Liu MW, et al. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. Am J Cardiol 1996;78:1042-1044.
24. Schomig A, Neumann PJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
25. Leon MB, Baim DS, Gordon P, et al. Clinical and angiographic results from the Stent Anticoagulation Regimen Study (STARS) (abstr). Circulation 1997;96:I685.
26. Monassier JP, Hamon M, Elias J, et al. Early versus late coronary stenting following acute myocardial infarction: Results of the STENTIM I Study (French Registry of Stenting in Acute Myocardial Infarction). Cathet Cardiovasc Diagn 1997;42:243-248.
27. Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States - analysis of national mortality data, 1968-1991. Am J Hematol 1995;50:84-90.
28. Schuhlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998;98:104-111.
29. Thacker, KM. New prescriptions for ticlid by year (1994-1997). Nutley, NJ Roche Laboratories, 1998.